Effect of Memantine on Prolonging Safe Driving in Early AD: A Pilot Study

0Citations
Citations of this article
8Readers
Mendeley users who have this article in their library.
Get full text

Abstract

Background To determine the feasibility of conducting an RCT on the potential effectiveness of memantine hydrochloride in prolonging safe driving in mild AD. Methods A placebo-controlled, double blind randomized trial was conducted. Forty-three individuals ≥60 with mild AD met screening criteria and were randomized. Driving ability was measured by a standardized on-road driving test. Outcomes were driving capacity at 6 and 12 months and completion of the 12-month intervention. Results Of 43 participants randomized, 59% of the memantine group and 52% of the placebo group completed the on-road test at 12 months (p = .66). All 13 memantine group participants maintained their driving status at 12 months, whereas only 8 of the 11 placebo group participants did (p = .040, OR = 4.45). Conclusions Results provide the framework for designing a rigorous multisite clinical trial of memantine effect on maintaining driving capacity in mild AD.

Cite

CITATION STYLE

APA

Holland, P. J., Tappen, R. M., Newman, D. O., Freeman-Costin, K. C., & Fisher, L. J. (2021). Effect of Memantine on Prolonging Safe Driving in Early AD: A Pilot Study. Canadian Geriatrics Journal, 24(4), 292–296. https://doi.org/10.5770/cgj.24.540

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free